Concepedia

Alexandra Buhles

AB

6

Publications

282

Citations

6

H-Index

2009

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

University College Cork

Mercy University Hospital

Alexandra Buhles is an author at Novartis (Switzerland) specializing in cancer cell biology, cell signaling, and drug discovery.

Top concepts

Publications per year

2009–2023

6

Publications

6

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

, , +19

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Weiss, Flavia Adler, Alexandra Buhles et al. · Molecular Cancer Therapeutics · 2019 · 95 citations

Therapeutic Assessment of Targeting ASNS Combined with <scp>l</scp> -Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms

Verena Apfel, Damien Bégué, Valentina Cordo’ et al. · ACS Pharmacology & Translational Science · 2021 · 31 citations · Full text

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol et al. · Cancer Research · 2023 · 24 citations · Full text

Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours

Alexandra Buhles, Sara Collins, Jan Peter van Pijkeren et al. · Genetic Vaccines and Therapy · 2009 · 14 citations · Full text

Rows per page

1–5 of 6